Tuesday, July 23, 2019 10:34 AM

NEW FOR 2020 AND BEYOND: DRY EYE DISEASE AGENTS IN PIPELINE

Originally believed to be primarily a disease of postmenopausal women with or without autoimmune disorders, it is now recognized that dry eye disease [1](DED) affects patients of both sexes at younger ages.

DED is a chronic condition, and although pharmacological and procedural treatments can improve clinical signs, there is no cure.Artificial tears generates close to $540 million in annual sales globally,1 and the U.S. spends more than $2 billion yearly on pharmaceuticals to treat DED.2[2]

Patients with Sjgrens syndrome[3] dry eye spend 78% more on western medicine than those without the autoimmune disorder DED.3 There continues to be an unmet need for more effective treatments for DED, as is evidenced from the multitude of clinical studies listed in Clinicaltrials.gov[4] that are under way or not yet recruiting.

Here is a brief overview of studies thats are nearing completion and some products that have been filed for regulatory approval.

RELATED: Understanding prevalence, demographics of dry eye disease

News source: GOOGLE NEWS

See also: EastRidgeEyeCenter